Emerging Updates in Front-Line Immunotherapy for Unresectable Hepatocellular Carcinoma (uHCC)
James J. Harding, MD, discusses how emerging front-line immunotherapies, particularly the combination of nivolumab and ipilimumab, are shaping the treatment landscape for unresectable hepatocellular carcinoma (uHCC), with a focus on efficacy, safety, and patient selection.
EP. 1: Evolving First-Line Treatment Strategies for uHCC.
December 19th 2024James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma (uHCC) based on NCCN Guidelines, and discusses the evolving treatment landscape, including the rationale for combination immunotherapy (IO) and how additional IO combinations may address unmet needs like depth of response and resistance.
Watch
EP. 2: An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.
January 2nd 2025James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).
Watch
